ArticleInternational journal of clinical and experimental pathology2025
Expression patterns and diagnostic efficacy of cytokeratin 19 and galectin-3 in thyroid neoplasms.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer is the world's most prevalent endocrine malignancy and a major health issue. With population aging and environmental influence, its incidence is increasing significantly. Highly specific and sensitive biomarkers to differentiate it from other thyroid diseases are crucial in clinical diagnosis. Identifying thyroid cancer types accurately is essential for personalized treatment, better survival, and improved prognosis.
methodsThis study was to demonstrate the survival prognosis of Cytokeratin19 (CK19) and Galectin-3 in thyroid cancer through the Kaplan-Meier plotter. Simultaneously, KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway database was used to detect the associated signaling pathways of CK19 and Galectin-3. Furthermore, a retrospective analysis was performed on 55 cases of thyroid tumor, including papillary thyroid carcinoma (PTC) and nodular goiter (NG), using immunohistochemistry (IHC) for these proteins. The ROC curve evaluated the diagnostic ability of CK19 and Galectin-3 expressions.
resultsLower levels of CK19 and Galectin-3 were associated with a poor overall survival prognosis (OS, P < 0.05). The KEGG pathway database demonstrated that the signaling pathways related to CK19 and Galectin-3 play a vital function in controlling the cell cycle. The research revealed that CK19 and Galectin-3 expressions were greater in PTC compared to NG (P < 0.01). Furthermore, in PTC, the positive expression of Galectin-3 was increased in the subgroup aged 55 years and above (P < 0.01). A positive correlation of PTC was identified between the expressions of CK19 and Galectin-3. Moreover, lymph node metastasis correlated positively with tumor size in PTC (P < 0.01). Both CK19 and Galectin-3 proteins have predictive values in predicting PTC (P < 0.05). Meanwhile, the AUC value for the optimal cut-off of combined CK19 and Galectin-3 is more statistically significant (P < 0.05).
conclusionCK19 and Galectin-3 are likely to be involved in the pathogenesis of thyroid neoplasms, manifesting distinct functions across diverse PTC subtypes. Furthermore, they may function as highly specific and sensitive biomarkers for differentiating pathological diagnoses, thus offering substantial value in the precise identification of thyroid-related pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.